// App-Quantinova.ai

: Indacaterol/glycopyrronium (IND/GLY) reduces days with COPD exacerbation vs salmeterol/fluticasone (SFC) independent of PRO tool: results of the FLAME study

Researchers

Presenter

  • Jadwiga Wedzicha

Principal Investigators

  • Kenneth R Chapman

  • Stefan-Marian Frent

  • Steven Shen

  • Francesco Patalano

  • Michael Larbig

  • Robert Fogel

  • Donald Banerji

Medical Centers

  • National Heart and Lung Institute, Imperial College London, London, United Kingdom

  • Department of Medicine, Asthma and Airway Centre, University Health Network, University of Toronto,, Toronto, Canada

  • European Respiratory Society Fellow at Novartis Pharma AG, Basel, (Switzerland); Department of Pulmonology, University of Medicine and Pharmacy “Victor Babes” Timisoara,, Timisoara, Romania

  • Novartis Pharmaceuticals Corporation East Hanover NJ United States

  • Novartis AG, Basel, Switzerland

Locations

  • United Kingdom

  • Canada

  • Romania

  • United States

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • salmeterol + fluticasone

  • Seebri Breezhaler

  • Fluticasone

  • Fluticasone furoate

  • indacaterol

  • Salmeterol Xinafoate

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved